Psoriasis
Not recruitingORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis
ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis
Germany- Participants:18–64 years · 65+ years
- Substances:ORKA-001
- Sponsor:Oruka Therapeutics Inc.
Rare diseases
Investigational molecules
Locations
Back to Germany1 333 clinical trials in Bad Nauheim, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis
GermanyRO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes
GermanyBaricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis
GermanyEfficacy and Safety of MET097 Once Weekly in People with Overweight or Obesity and Type 2 Diabetes
GermanyA study to evaluate the efficacy and safety of MET097 in people with obesity or overweight.
GermanyA study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis
GermanyA study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)
GermanyStudy of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease
GermanyA study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia
GermanyA study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease
GermanyTesting Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned
GermanyA Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread
GermanyThe busiest research cities in the country
What the registry says about research in the country
Innovative studies focusing on hypertrophic cardiomyopathy treatments, including trials of mavacamten and aficamten. Research also covers advanced therapies for heart failure and pulmonary hypertension management.
Long-term safety and efficacy evaluations of novel cardiovascular medications are prioritized.
Advanced research in breast cancer treatment, particularly focusing on HER2-negative and triple-negative variants. Studies evaluate innovative combination therapies including atezolizumab and targeted treatments.
Emphasis on improving survival rates and reducing recurrence in early-stage breast cancer.
Clinical investigations of inflammatory diseases including myositis and arteritis. Studies evaluate new biological treatments and their long-term effectiveness in managing chronic inflammatory conditions.
Focus on developing targeted therapies for better disease control and improved patient outcomes.
Tell us about your condition – we search every trial in Europe and connect you with the right site.